CSF1 and neoplasm: Yu’s group developed an intelligent nanodrug PFH@LSLP that can target CXCR4, which is highly expressed under tumor hypoxic conditions, and deliver both sorafenib and CSF1/CSF1R inhibitor PLX3397 [30].